Literature DB >> 31770540

Over the counter naloxone needed to save lives in the United States.

Corey S Davis1, Derek Carr2.   

Abstract

The United States continues to face a public health emergency of opioid-related harm, the effects of which could be dramatically reduced through increased access to the opioid antagonist naloxone. Unfortunately, naloxone is too often unavailable when and where it is most needed, partly due to its continued status as a prescription medication. Although states and the federal Food and Drug Administration (FDA) have acted to increase access to naloxone, these changes are insufficient to address this unprecedented crisis. In this Commentary, we argue that FDA can and should immediately reclassify naloxone from prescription-only to over-the-counter status, a change that could save hundreds if not thousands of lives in the United States every year.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Law; Naloxone; Opioids; Overdose

Mesh:

Substances:

Year:  2019        PMID: 31770540     DOI: 10.1016/j.ypmed.2019.105932

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  6 in total

1.  A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder.

Authors:  Jermaine D Jones; Aimee N Campbell; Laura Brandt; Verena E Metz; Suky Martinez; Melanie Wall; Thomas Corbeil; Howard Andrews; Felipe Castillo; Joanne Neale; John Strang; Stephen Ross; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2022-05-23       Impact factor: 4.852

2.  Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018.

Authors:  Christopher Dunphy; Kun Zhang; Gery P Guy; Christopher M Jones
Journal:  Prev Med       Date:  2021-09-29       Impact factor: 4.637

3.  Expert views on state-level naloxone access laws: a qualitative analysis of an online modified-Delphi process.

Authors:  Sean Grant; Rosanna Smart
Journal:  Harm Reduct J       Date:  2022-06-08

4.  Opioid Policy Changes During the COVID-19 Pandemic - and Beyond.

Authors:  Corey S Davis; Elizabeth A Samuels
Journal:  J Addict Med       Date:  2020 Jul/Aug       Impact factor: 3.702

5.  Effectiveness and implementability of state-level naloxone access policies: Expert consensus from an online modified-Delphi process.

Authors:  Rosanna Smart; Sean Grant
Journal:  Int J Drug Policy       Date:  2021-07-30

Review 6.  Considering the Potential Benefits of Over-the-Counter Naloxone.

Authors:  Kirk E Evoy; Lucas G Hill; Corey S Davis
Journal:  Integr Pharm Res Pract       Date:  2021-02-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.